Antibiotics and Cure Rates in Childhood Febrile Urinary Tract Infections in Clinical Trials: A Systematic Review and Meta-analysis
- 142 Downloads
Urinary tract infections (UTIs) are common bacterial infections among children.
To systematically review the antimicrobials used for febrile UTIs in paediatric clinical trials and meta-analyse the observed cure rates and reasons for treatment failure.
Materials and Methods
We searched Medline, Embase and Cochrane central databases between January 1, 1990, and November 24, 2016, combining MeSH and free-text terms for: “urinary tract infections”, AND “therapeutics”, AND “clinical trials” in children (age range 0–18 years). Two independent reviewers assessed study quality and performed data extraction. The major outcome measures were clinical and microbiological cure rates according to different antibiotics.
We identified 2762 published studies and included 30 clinical trials investigating 3913 cases of paediatric febrile urinary tract infections. Children with no underlying condition were the main population included in the trials (n = 2602; 66.5%). Cephalosporins were the most frequent antibiotics studied in trials (22/30, 73.3%). Only a few antibiotics active against resistant UTIs have been tested in randomised clinical trials, mainly aminoglycosides. The average point cure rate of all investigational drugs was estimated to 95.3% (95% CI 93.5–96.9%). Among 3002 patients for whom cure and failure rates were reported, only 3.9% (3.9%; 118/3002) were considered clinically to have treatment failure, while 135 (4.5%; 135/3002) had microbiological failure.
We observed high treatment cure rates, regardless of the investigational drug chosen, the route of administration, duration and dosing. This suggests that future research should prioritise observational studies and clinical trials on children with multi-drug-resistant infections.
KV, RB and YH conceptualized and designed the work. KV, RB, JB and LF identified eligible studies. KV, RB and LF appraised study quality; data were extracted, transformed and analysed by KV and RB. Data analysis was guided by YH. MS and TZ contributed substantially to data interpretation. KV and RB drafted the initial manuscript. JB, LF, TZ, MS and YH critically revised the manuscript for important intellectual content. All authors contributed to, reviewed, and approved the final version to be published. All authors received access to all the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. YH is the guarantor.
Compliance with Ethical Standards
No external funding for this manuscript.
Conflict of interest
MS reports grants from GlaxoSmithKline, Pfizer and Cubist Pharmaceuticals, outside the submitted work. JB’s husband is senior corporate counsel at Novartis International AG, Basel, Switzerland, and holds Novartis stock and stock options. The other authors have no conflicts of interest to disclose.
- 6.WHO. Antimicrobial Resistance. Global report on surveillance. 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/ Accessed 29 Jan 2018.
- 12.FDA. FDA Drug Safety Podcast: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. 2013. https://www.fda.gov/drugs/drugsafety/ucm369580.htm Accessed 29 Jan 2018.
- 18.Miller JJ. Inverse of Freeman-Tukey double arcsine transformation. Am Stat. 1978;32(4):138.Google Scholar
- 21.Allameh Z, Karimi A, Tabatabaei SR, Sharifian M, Sal2372Tuberculamzadeh J. Effect of n-acetylcysteine on inflammation biomarkers in pediatric acute pyelonephritis: a randomized controlled trial. Iran J Kidney Dis. 2015;9(6):454–62.Google Scholar
- 31.Francois P, Bensman A, Begue P, Artaz MA, Coudeville L, Lebrun T et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial IV combination therapy. [French]. Medecine et Maladies Infectieuses. 1997;27(SPEC. ISS. JUNE):667–73.CrossRefGoogle Scholar
- 33.Huang YY, Chen MJ, Chiu NT, Chou HH, Lin KY, Chiou YY. Adjunctive oral methylprednisolone in pediatric acute pyelonephritis alleviates renal scarring. Pediatrics. 2011;128(3):2010.Google Scholar
- 40.Pena DA, Viviani ST, le Corre PN, Morales MV, Montecinos BC, Gajardo SC. Treatment of urinary tract infections in febrile infants: Experience of outpatient intravenous antibiotic treatment. [Spanish]. Revista Chilena de Infectologia. 2009;26(4):350–4.Google Scholar
- 45.Vigano A, Principi N. Aminoglycosides in paediatric infections: the role of isepamicin. [Italian]. Clin Drug Investig. 1996;12(SUPPL. 1):37–46.Google Scholar
- 46.Vigano A, Principi N, Brivio L, Tommasi P, Stasi P, Villa AD. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother. 1992;36(7):1499–503.CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Vilaichone A, Watana D, Chaiwatanarat T. Oral ceftibuten switch therapy for acute pyelonephritis in children. J Med Assoc Thailand Chotmaihet thangphaet. 2001;84;(suppl 1):S61–S67.Google Scholar
- 48.Yosefichaijan P, Khabazi M, Pakniyat A, Goudarzi. Therapeutic effect of complementary Vitamin C on pediatrics urinary tract infection. Pediatr Nephrol. 2016;31 (10):1796.Google Scholar
- 58.Finnell SME. Urinary tract infection in children: an update. Open Urol Nephrol J. 2015;8(Suppl 3: M2):92–5.Google Scholar
- 59.Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2014;7:CD003772.Google Scholar
- 61.Vouloumanou EK, Rafailidis PI, Kazantzi MS, Athanasiou S, Falagas ME. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Curr Med Res Opin. 2008;24(12):3423–34.CrossRefPubMedGoogle Scholar
- 68.US Department of Health and Human Services; Food and Drug Administration. Guidance for industry. Complicated urinary tract infections and pyelonephritis: developing antimicrobial drugs for treatment. Draft guidance. 1998. www.fda.gov/ohrms/dockets/98fr/2559dft.pdf. Accessed 29 Jan 2018.